Recurrent Childhood Acute Lymphoblastic Leukemia Recruiting Phase 2 Trials for Inotuzumab ozogamicin (DB05889)

IndicationStatusPhase
DBCOND0028597 (Recurrent Childhood Acute Lymphoblastic Leukemia)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs